Metraipolis › archive › dc_c7642d2f577a

Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center… — Europe PMC PMID:42459641

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42459641
DOI
10.3389/fimmu.2026.1841762
License (as archived)
solo-consultazione
Archived
2026-10-18T14:03:19.056Z
SHA-256 of the archived text
d88a1f6f97dcedb1f163221cf70d198ef47bda941dc5aba90789dd39fc0447e3
Stable URL of this page
https://metraipolis.com/documento/dc_c7642d2f577a

How to cite

Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center… — Europe PMC PMID:42459641 — Europe PMC (en), https://europepmc.org/article/MED/42459641 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c7642d2f577a (Metraipolis archive dc_c7642d2f577a, sha256 d88a1f6f97dcedb1f163221cf70d198ef47bda941dc5aba90789dd39fc0447e3)
BibTeX
@misc{dcc7642d2f577a,
  title = {Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center… — Europe PMC PMID:42459641},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42459641},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c7642d2f577a; sha256 d88a1f6f97dcedb1f163221cf70d198ef47bda941dc5aba90789dd39fc0447e3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42459641. Agents can read the archived copy with the MCP tool read_document.